Case report: A sustained survival benefit of third-line immunotherapy for refractory thymic carcinoma

Case report: A sustained survival benefit of third-line immunotherapy for refractory thymic carcinoma

Thymic carcinoma (TC) is an uncommon type of thymic epithelial tumors. Patients with relapsed or refractory TCs have a poor prognosis. Immune checkpoint inhibitor monotherapy can be applied as a second-line treatment for such cases. This study reported a TC patient who did not respond to conventiona...

Full description

Saved in:
Bibliographic Details
Main Authors: Mi Meng, Bo Yu, Jie Luo, Yuju Bai, Lin Li, Shicheng Chen, Sisi He, Hu Ma
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-07-01
Series:Frontiers in Oncology
Subjects:
sintilimab
thymic carcinoma(TC)
therapeutic option
case report
anti-PD-1
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1326006/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items